{"id":55183,"date":"2026-01-22T21:21:41","date_gmt":"2026-01-22T13:21:41","guid":{"rendered":"https:\/\/flcube.com\/?p=55183"},"modified":"2026-01-22T21:21:43","modified_gmt":"2026-01-22T13:21:43","slug":"china-isotope-radiation-corporation-signs-commercial-deal-for-pluvicto-chinas-first-psma-radioligand-therapy","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55183","title":{"rendered":"China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy"},"content":{"rendered":"\n<p><strong>China Isotope &amp; Radiation Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1763:HKG\">HKG: 1763<\/a>) announced it has officially entered into a commercial cooperation agreement with <strong>Novartis Pharmaceutical Technology (Zhejiang) Co., Ltd.<\/strong> for <strong>Pluvicto (177Lu vipivotide tetraxetan injection)<\/strong>, the first and only approved <strong>PSMA\u2011targeted radioligand therapy (RLT)<\/strong> in China for advanced prostate cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-partnership-terms\">Deal Structure &amp; Partnership Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Partners<\/strong><\/td><td>China Isotope &amp; Radiation Corporation \/ Novartis Pharmaceutical Technology (Zhejiang)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Mainland China<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Pluvicto (177Lu vipivotide tetraxetan injection)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Advanced prostate cancer (metastatic castration\u2011resistant)<\/td><\/tr><tr><td><strong>Deal Type<\/strong><\/td><td>Commercial cooperation agreement<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td><strong>First PSMA\u2011targeted radioligand therapy<\/strong> approved and launched in China<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>Positions China Isotope as a leader in targeted radiopharmaceuticals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-clinical-innovation\">Drug Profile &amp; Clinical Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>PSMA\u2011targeted radioligand therapy (RLT)<\/strong> delivers targeted beta radiation via Lutetium\u2011177 to prostate\u2011specific membrane antigen (PSMA)\u2013expressing cancer cells.<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> First and currently the only approved RLT of its kind in China, offering a precision\u2011medicine approach for late\u2011stage prostate cancer patients.<\/li>\n\n\n\n<li><strong>Clinical Value:<\/strong> Demonstrates ability to <strong>extend overall survival and improve quality of life<\/strong> in patients with limited treatment options.<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Outpatient intravenous infusion, enabling integration into standard oncology workflows.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Prostate Cancer Burden:<\/strong> Over <strong>120,000 new prostate cancer cases<\/strong> annually, with metastatic disease representing a growing segment as screening improves.<\/li>\n\n\n\n<li><strong>Market Potential:<\/strong> Analysts project <strong>\u00a5800\u202fmillion\u20131.2\u202fbillion<\/strong> (US$110\u2013170\u202fmillion) peak annual sales for Pluvicto in China, assuming 10\u201315% penetration of eligible advanced patients by 2028.<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage:<\/strong> As the sole approved PSMA\u2011targeted RLT, Pluvicto faces no direct competition, though it must navigate hospital radiopharmacy infrastructure requirements.<\/li>\n\n\n\n<li><strong>China Isotope\u2019s Strategy:<\/strong> The partnership leverages China Isotope\u2019s established radiopharmaceutical distribution network and regulatory expertise to accelerate market access and patient reach.<\/li>\n\n\n\n<li><strong>Patient Access:<\/strong> Inclusion in the <strong>National Reimbursement Drug List (NRDL)<\/strong> discussions for 2026 could unlock broad reimbursement and drive volume growth.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief includes forward\u2011looking statements regarding commercial expectations, market penetration, and revenue projections for Pluvicto in China. Actual results may differ due to regulatory approvals, hospital adoption rates, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2025121501469_c-1.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025121501469_c.\"><\/object><a id=\"wp-block-file--media-e3948d0b-717d-425f-9644-70afe4ebf757\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2025121501469_c-1.pdf\">2025121501469_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2025121501469_c-1.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e3948d0b-717d-425f-9644-70afe4ebf757\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China Isotope &amp; Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,2962,1033,140],"class_list":["post-55183","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cancer","tag-china-isotope-radiation-corporation","tag-hkg-1763","tag-novartis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China Isotope &amp; Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial cooperation agreement with Novartis Pharmaceutical Technology (Zhejiang) Co., Ltd. for Pluvicto (177Lu vipivotide tetraxetan injection), the first and only approved PSMA\u2011targeted radioligand therapy (RLT) in China for advanced prostate cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55183\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy\" \/>\n<meta property=\"og:description\" content=\"China Isotope &amp; Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial cooperation agreement with Novartis Pharmaceutical Technology (Zhejiang) Co., Ltd. for Pluvicto (177Lu vipivotide tetraxetan injection), the first and only approved PSMA\u2011targeted radioligand therapy (RLT) in China for advanced prostate cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55183\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T13:21:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T13:21:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55183#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55183\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy\",\"datePublished\":\"2026-01-22T13:21:41+00:00\",\"dateModified\":\"2026-01-22T13:21:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55183\"},\"wordCount\":355,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"China Isotope &amp; Radiation Corporation\",\"HKG: 1763\",\"Novartis\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55183#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55183\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55183\",\"name\":\"China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-22T13:21:41+00:00\",\"dateModified\":\"2026-01-22T13:21:43+00:00\",\"description\":\"China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial cooperation agreement with Novartis Pharmaceutical Technology (Zhejiang) Co., Ltd. for Pluvicto (177Lu vipivotide tetraxetan injection), the first and only approved PSMA\u2011targeted radioligand therapy (RLT) in China for advanced prostate cancer.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55183#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55183\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55183#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy - Insight, China&#039;s Pharmaceutical Industry","description":"China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial cooperation agreement with Novartis Pharmaceutical Technology (Zhejiang) Co., Ltd. for Pluvicto (177Lu vipivotide tetraxetan injection), the first and only approved PSMA\u2011targeted radioligand therapy (RLT) in China for advanced prostate cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55183","og_locale":"en_US","og_type":"article","og_title":"China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy","og_description":"China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial cooperation agreement with Novartis Pharmaceutical Technology (Zhejiang) Co., Ltd. for Pluvicto (177Lu vipivotide tetraxetan injection), the first and only approved PSMA\u2011targeted radioligand therapy (RLT) in China for advanced prostate cancer.","og_url":"https:\/\/flcube.com\/?p=55183","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-22T13:21:41+00:00","article_modified_time":"2026-01-22T13:21:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55183#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55183"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy","datePublished":"2026-01-22T13:21:41+00:00","dateModified":"2026-01-22T13:21:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55183"},"wordCount":355,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","China Isotope &amp; Radiation Corporation","HKG: 1763","Novartis"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55183#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55183","url":"https:\/\/flcube.com\/?p=55183","name":"China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-22T13:21:41+00:00","dateModified":"2026-01-22T13:21:43+00:00","description":"China Isotope & Radiation Corporation (HKG: 1763) announced it has officially entered into a commercial cooperation agreement with Novartis Pharmaceutical Technology (Zhejiang) Co., Ltd. for Pluvicto (177Lu vipivotide tetraxetan injection), the first and only approved PSMA\u2011targeted radioligand therapy (RLT) in China for advanced prostate cancer.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55183#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55183"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55183#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China Isotope &amp; Radiation Corporation Signs Commercial Deal for Pluvicto, China\u2019s First PSMA Radioligand Therapy"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55183","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55183"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55183\/revisions"}],"predecessor-version":[{"id":55188,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55183\/revisions\/55188"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55183"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55183"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55183"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}